Thermo Fisher Scientific (HAM:TN8) Cyclically Adjusted Revenue per Share: €92.73 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HAM:TN8 Thermo Fisher Scientific Inc HAM:TN8
85 GF Score
Price €488.00
GF Value €501.06
Valuation Fairly Valued
! 8 Warning Signs
View Full Analysis

What is Thermo Fisher Scientific Cyclically Adjusted Revenue per Share?

Thermo Fisher Scientific HAM:TN8 -1.13% 85 Cyclically Adjusted Revenue per Share is €92.73 as of Jun. 2026. GuruFocus rates HAM:TN8 with a GF Score™ of 85/100 and a GF Value™ of €501.06 (Fairly Valued). The stock has 8 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Thermo Fisher Scientific's adjusted revenue per share for the three months ended in Jun. 2026 was €28.061. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €92.73 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Thermo Fisher Scientific's average Cyclically Adjusted Revenue Growth Rate was 10.30% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 10.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 13.50% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Thermo Fisher Scientific was 16.50% per year. The lowest was -1.30% per year. And the median was 9.50% per year.

As of today (2026-07-29), Thermo Fisher Scientific's current stock price is €488.00. Thermo Fisher Scientific's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €92.73. Thermo Fisher Scientific's Cyclically Adjusted PS Ratio of today is 5.26.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Thermo Fisher Scientific was 10.98. The lowest was 4.16. And the median was 6.43.


Thermo Fisher Scientific  (HAM:TN8) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Thermo Fisher Scientific's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=488.00/92.73
=5.26

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Thermo Fisher Scientific was 10.98. The lowest was 4.16. And the median was 6.43.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Thermo Fisher Scientific Cyclically Adjusted Revenue per Share Related Terms


Thermo Fisher Scientific Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Thermo Fisher Scientific's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thermo Fisher Scientific Cyclically Adjusted Revenue per Share Chart

Thermo Fisher Scientific Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 84.25

Thermo Fisher Scientific Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 84.25 87.26 92.73

HAM:TN8 vs DHR, IDXX, A: Cyclically Adjusted Revenue per Share Comparison

For the Diagnostics & Research subindustry, Thermo Fisher Scientific's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Thermo Fisher Scientific Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Thermo Fisher Scientific's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Thermo Fisher Scientific's Cyclically Adjusted PS Ratio falls into.


HAM:TN8
85GF Score
Thermo Fisher Scientific Inc HAM:TN8
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Thermo Fisher Scientific Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Thermo Fisher Scientific's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=28.061/333.9520*333.9520
=28.061

Current CPI (Jun. 2026) = 333.9520.

Thermo Fisher Scientific Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 10.069 241.428 13.928
201612 11.869 241.432 16.417
201703 11.308 243.801 15.489
201706 11.301 244.955 15.407
201709 10.731 246.819 14.519
201712 12.648 246.524 17.134
201803 11.692 249.554 15.646
201806 12.815 251.989 16.983
201809 12.496 252.439 16.531
201812 14.088 251.233 18.727
201903 13.451 254.202 17.671
201906 13.870 256.143 18.083
201909 14.096 256.759 18.334
201912 15.251 256.974 19.820
202003 14.095 258.115 18.236
202006 15.433 257.797 19.992
202009 18.131 260.280 23.263
202012 21.735 260.474 27.866
202103 20.960 264.877 26.426
202106 19.436 271.696 23.890
202109 19.976 274.310 24.319
202112 23.857 278.802 28.576
202203 27.166 287.504 31.555
202206 26.339 296.311 29.685
202209 27.301 296.808 30.718
202212 27.573 296.797 31.025
202303 25.781 301.836 28.524
202306 25.423 305.109 27.826
202309 25.536 307.789 27.707
202312 25.728 306.746 28.010
202403 24.785 312.332 26.501
202406 25.568 314.175 27.177
202409 24.867 315.301 26.338
202412 28.413 315.605 30.065
202503 25.295 319.799 26.414
202506 24.895 322.561 25.774
202509 25.069 324.800 25.775
202512 27.597 324.054 28.440
202603 25.521 330.213 25.810
202606 28.061 333.952 28.061

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €92.73 mean?
Thermo Fisher Scientific (HAM:TN8) has a Cyclically Adjusted Revenue per Share of €92.73 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Thermo Fisher Scientific and its competitors.
Is Thermo Fisher Scientific's Cyclically Adjusted Revenue per Share too high?
Thermo Fisher Scientific's current Cyclically Adjusted Revenue per Share is €92.73. Overall, Thermo Fisher Scientific has a GF Score™ of 85/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Thermo Fisher Scientific's Cyclically Adjusted Revenue per Share compare to DHR and IDXX?
Thermo Fisher Scientific's Cyclically Adjusted Revenue per Share of €92.73 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Diagnostics & Research company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Diagnostics & Research industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Thermo Fisher Scientific and its competitors. Thermo Fisher Scientific's current Cyclically Adjusted Revenue per Share is €92.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thermo Fisher Scientific stock overvalued right now?
Based on GuruFocus' analysis, Thermo Fisher Scientific (HAM:TN8) is currently considered Fairly Valued. The stock's GF Value™ is €501.06, compared to a current price of €488.00 — trading 2.6% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €92.73. Thermo Fisher Scientific's overall GF Score™ is 85/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Thermo Fisher Scientific (HAM:TN8), the current Cyclically Adjusted Revenue per Share is €92.73 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Thermo Fisher Scientific (HAM:TN8) Overvalued in 2026?

Based on GuruFocus' analysis, Thermo Fisher Scientific stock appears to be undervalued. The current stock price of €488.00 is trading 2.6% below its estimated GF Value™ of €501.06. GuruFocus considers Thermo Fisher Scientific to be Fairly Valued.

Key valuation signals for HAM:TN8:

  • Cyclically Adjusted Revenue per Share: €92.73
  • GF Value™: €501.06 vs. price of €488.00 (2.6% below fair value)
  • GF Score™: 85/100 with 8 warning signs

No single metric tells the full story. See the HAM:TN8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Thermo Fisher Scientific Business Description

Address 168 Third Avenue, Waltham, MA, USA, 02451
Thermo Fisher Scientific sells scientific instruments and laboratory equipment, diagnostics consumables, and life science reagents. The firm operates through four segments as of year-end 2025 (revenue figures include some cross-segment revenue): analytical technologies (17% of sales); specialty diagnostic products (11%); life science solutions (23%); and lab products and services, which includes CRO services (the remainder).
85GF Score

Get the complete analysis for HAM:TN8

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€488.00
Price
€501.06
GF Value